I-Flow predicts growth phase, PLC prepares for "pivotal period"
This article was originally published in Clinica
Executive Summary
Curis, the result of a three-way merger between Creative BioMolecules, Ontogeny and Reprogenesis in July 2000, has completed its first fiscal year. The Cambridge, Massachusetts company says that, because of the merger and associated charges, a comparison of previous years' business with that of the period under review does not provide a true reflection of current performance.